Shopping Cart

No products in the cart.

SCWD Publications Digest

Staying informed on the latest in cachexia, sarcopenia, and wasting disorders research is essential yet challenging. The SCWD Digest offers concise updates and expert insights into significant studies and developments. We highlight and link directly to leading research, making it easier for healthcare professionals to access and apply groundbreaking findings. Our goal: empower the medical community to advance patient care worldwide efficiently.

Cachexia and Sarcopenia in Oligometastatic Non-Small Cell Lung Cancer: Making a Potential Curable Disease Incurable?

Among patients with advanced NSCLC, there is a group of patients with synchronous oligometastatic disease (sOMD), defined as a limited number of metastases detected at the time of diagnosis. As cachexia and sarcopenia are linked to poor survival, incorporating this...
Read MoreCachexia and Sarcopenia in Oligometastatic Non-Small Cell Lung Cancer: Making a Potential Curable Disease Incurable?

Cachexia: A systemic consequence of progressive, unresolved disease

Cachexia, a systemic wasting condition, is considered a late consequence of diseases, including cancer, organ failure, or infections, and contributes to significant morbidity and mortality. The induction process and mechanistic progression of cachexia are incompletely understood. Refocusing academic efforts away...
📰 Journal: Cell
Read MoreCachexia: A systemic consequence of progressive, unresolved disease

Body composition and lung cancer-associated cachexia in TRACERx.

Cancer-associated cachexia (CAC) is a major contributor to morbidity and mortality in individuals with non-small cell lung cancer. Key features of CAC include alterations in body composition and body weight. Here, we explore the association between body composition and body...
📰 Journal: Nat Med
Read MoreBody composition and lung cancer-associated cachexia in TRACERx.

NAD repletion with niacin counteracts cancer cachexia.

Cachexia is a debilitating wasting syndrome and highly prevalent comorbidity in cancer patients. It manifests especially with energy and mitochondrial metabolism aberrations that promote tissue wasting. We recently identified nicotinamide adenine dinucleotide (NAD) loss to associate with muscle mitochondrial dysfunction...
📰 Journal: Nat Commun
Read MoreNAD repletion with niacin counteracts cancer cachexia.

An Evaluation of Multimodal Interventions for Co-morbid Frailty and Type 2 Diabetes Mellitus

This study investigates multimodal interventions for older adults with frailty and Type 2 Diabetes Mellitus (T2DM), focusing on the effects of physical, nutritional, and educational strategies on improving functional performance. Involving 843 individuals aged 70+, findings highlight improved mobility, especially gait speed, linked to adherence and baseline health. Published in 'Age and Ageing', the research by Alvarez-Bustos A, Laosa O, Marzetti E, et al., emphasizes tailored interventions' importance for T2DM and frailty in the elderly.
📰 Journal: Age and Ageing
Read MoreAn Evaluation of Multimodal Interventions for Co-morbid Frailty and Type 2 Diabetes Mellitus

Assessing the Clinical Relevance of the C-Reactive Protein-Triglyceride-Glucose Index in Cancer Cachexia

This research uncovers the clinical significance of the C-reactive protein-triglyceride-glucose index (CTI) in predicting survival outcomes in cancer cachexia (CC). Demonstrating superior predictive accuracy over CRP or TyG indices alone, the study reveals CTI's correlation with increased mortality risks and its potential to refine patient management strategies in CC. Published in 'Cancer and Metabolism', January 2024, by Ruan GT, Deng L, Xie HL, et al., this work highlights CTI's pivotal role in enhancing prognosis and guiding treatment in CC.
📰 Journal: Cancer and Metabolism
Read MoreAssessing the Clinical Relevance of the C-Reactive Protein-Triglyceride-Glucose Index in Cancer Cachexia

Cancer Cachexia: Molecular Mechanisms and Therapeutic Strategies

This comprehensive review sheds light on cancer cachexia (CC), a significant condition marked by muscle wasting in cancer patients, emphasizing its molecular mechanisms and potential treatments. Highlighting the challenge CC presents, especially in older individuals, the article discusses the multifaceted approach needed to combat this syndrome.
📰 Journal: Clinical Nutrition
Read MoreCancer Cachexia: Molecular Mechanisms and Therapeutic Strategies

Sarcopenia Metrics and Quality of Life Components: What Is the Link?

Sarcopenia is known to be negatively associated with quality of life in affected patients. However, the individual impacts of its metrics, i.e. muscle mass, strength, and physical performance, on patients’ overall quality of life remain to be thoroughly investigated. This pre-printed study aimed to characterise the associations between sarcopenia metrics and quality of life outcomes in community-dwelling older adults from the SOMMA (Study of Muscle, Mobility and Aging) study. Health-related quality of life was ascertained using the EQ-5D questionnaire, which measures 5 subcomponents: mobility, self-care, usual activities, pain and discomfort, as well as anxiety and depression.
Read MoreSarcopenia Metrics and Quality of Life Components: What Is the Link?

Sarcopenia and Type 2 Diabetes: A Bidirectional Relationship

Sarcopenia is characterised by age-related reductions in skeletal muscle strength, mass, and functional ability. Importantly, sarcopenia is a multifactorial condition associated with metabolic alterations, including poor glucose disposal, insulin resistance, decreased metabolic rate and, thus, type 2 diabetes (T2D). Developing non-pharmaceutical guidelines for the prevention and treatment of both diseases when they coexist is essential to optimise patient health and reduce premature mortality within this patient population. This review aimed to examine 1) the pathophysiological link between sarcopenia and T2D, and 2) lifestyle interventions with the potential to mitigate both sarcopenia and T2D.
Read MoreSarcopenia and Type 2 Diabetes: A Bidirectional Relationship

Leucine-enriched Protein Supplementation for the Pre-frail: What Are the Benefits?

It is known that one in five adults with pre-frailty progresses to frailty over a 3-year period. Low protein and energy intake, increased prevalence of multimorbidity, and a sedentary lifestyle are well-characterised drivers of sarcopenia. Consequently, they act as catalysts of older adults’ transition to frailty. In this vein, stimulating increased muscle protein synthesis through regular physical exercise and protein-enriched diet consumption is pivotal for pre-frail older adults. Current U.S. Food and Nutrition Board guidelines recommend a dietary allowance of 0.8 g/kg of protein per day for older adults. However, this amount may be insufficient for those with pre-frailty due to their low-grade inflammation, multimorbidity, and increased susceptibility to anabolic resistance. This study aimed to examine the impact of leucine-enriched protein supplementation with or without exercise on 1) physical function, 2) body composition, and 3) systemic inflammation in pre-frail older adults with a daily protein consumption of ≤1 g/kg.
Read MoreLeucine-enriched Protein Supplementation for the Pre-frail: What Are the Benefits?

GDF-15: a mediator of exercise’s link with late-life weight loss?

Ageing is often associated with appetite reduction and ensuing weight loss. Although it is known that physical activity (PA) can prevent these ageing-related processes, the exact molecular mechanisms underpinning this ability remain unknown. Recent research has highlighted the role of exerkines, i.e. proteins released during and after PA, in controlling energy metabolism. Growth differentiation factor 15 (GDF-15), a stress-signalling cytokine secreted during PA and involved in ageing, exercise, and appetite control, has emerged as a potential mediator of late-life, ageing-related weight loss. This study aimed to explore the associations between PA, GDF-15, and body weight changes in older adults enrolled in the Multidomain Alzheimer Preventive Trial over a 3-year period.
📰 Journal: Journal of Cachexia, Sarcopenia and Muscle
Read MoreGDF-15: a mediator of exercise’s link with late-life weight loss?

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!